- Home
- MMI vs AUPH Comparison
MMI vs AUPH Comparison
Compare MMI & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MMI
- AUPH
- Stock Information
- Founded
- MMI 1971
- AUPH 1993
- Country
- MMI United States
- AUPH Canada
- Employees
- MMI N/A
- AUPH N/A
- Industry
- MMI Real Estate
- AUPH Biotechnology: Pharmaceutical Preparations
- Sector
- MMI Finance
- AUPH Health Care
- Exchange
- MMI Nasdaq
- AUPH Nasdaq
- Market Cap
- MMI 1.2B
- AUPH 1.4B
- IPO Year
- MMI 2013
- AUPH 1999
- Fundamental
- Price
- MMI $32.06
- AUPH $11.70
- Analyst Decision
- MMI Sell
- AUPH Strong Buy
- Analyst Count
- MMI 2
- AUPH 4
- Target Price
- MMI $30.00
- AUPH $12.25
- AVG Volume (30 Days)
- MMI 97.9K
- AUPH 2.6M
- Earning Date
- MMI 08-07-2025
- AUPH 07-31-2025
- Dividend Yield
- MMI 1.56%
- AUPH N/A
- EPS Growth
- MMI N/A
- AUPH N/A
- EPS
- MMI N/A
- AUPH 0.42
- Revenue
- MMI $711,994,000.00
- AUPH $260,111,000.00
- Revenue This Year
- MMI $12.22
- AUPH $12.15
- Revenue Next Year
- MMI $23.33
- AUPH $18.34
- P/E Ratio
- MMI N/A
- AUPH $27.83
- Revenue Growth
- MMI 14.79
- AUPH 25.59
- 52 Week Low
- MMI $27.61
- AUPH $5.20
- 52 Week High
- MMI $42.80
- AUPH $11.80
- Technical
- Relative Strength Index (RSI)
- MMI 56.38
- AUPH 81.92
- Support Level
- MMI $30.28
- AUPH $8.73
- Resistance Level
- MMI $31.75
- AUPH $9.37
- Average True Range (ATR)
- MMI 0.85
- AUPH 0.52
- MACD
- MMI -0.02
- AUPH 0.27
- Stochastic Oscillator
- MMI 72.95
- AUPH 96.92
About MMI Marcus & Millichap Inc.
Marcus & Millichap Inc is a national brokerage firm specializing in commercial real estate investment sales, financing, research, and advisory services. The company offers three primary services to its clients: commercial real estate investment brokerage, financing, and ancillary services, including other research, advisory, and consulting services. The company generates revenues by collecting fees on the sale and financing of commercial properties. These fees consist of commissions collected upon the sale of a property and fees collected from the placement of loans.
About AUPH Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.